We report a novel combination of factors that explains almost 60% of variable response to warfarin. Warfarin is a widely used anticoagulant, which acts through interference with vitamin K epoxide reductase that is encoded by VKORC1. In the next step of the vitamin K cycle, gamma-glutamyl carboxylase encoded by GGCX uses reduced vitamin K to activate clotting factors. We genotyped 201 warfarin-treated patients for common polymorphisms in VKORC1 and GGCX. All the five VKORC1 single-nucleotide polymorphisms covary significantly with warfarin dose, and explain 29-30% of variance in dose. Thus, VKORC1 has a larger impact than cytochrome P450 2C9, which explains 12% of variance in dose. In addition, one GGCX SNP showed a small but significant effect on warfarin dose. Incorrect dosage, especially during the initial phase of treatment, carries a high risk of either severe bleeding or failure to prevent thromboembolism. Genotype-based dose predictions may in future enable personalised drug treatment from the start of warfarin therapy.
INTRODUCTION
Warfarin is the most widely prescribed anticoagulant for thromboembolic therapy in North America and Europe. 1 It is used in atrial fibrillation, recurrent stroke, deep vein thrombosis, pulmonary embolism, and in patients with heart valve prosthesis. 2, 3 The therapeutic response is possible to measure by the prothrombin time international normalised ratio (PT INR); 4 nevertheless, warfarin is difficult to handle because of a narrow therapeutic range and a 20-fold inter-individual variation in dose requirement. 5, 6 Incorrect dosage, especially during the initial phase of treatment, carries a high risk of either severe bleeding or failure to prevent thromboembolism. 6 Haemorrhage during warfarin therapy is actually one of the leading causes of drug-related death in many Western countries. [6] [7] [8] [9] [10] Environmental and genetic factors influence the dose of warfarin necessary for a therapeutic response. 11 Factors such as age, bodyweight, diet and concomitant medication are well known to affect dose requirement. 3, [12] [13] [14] Variation in warfarin pharmacokinetics is another important factor influencing dose. warfarin dose. 15 Two variants that encode enzymes with single amino-acid substitutions, CYP2C9*2 and CYP2C9*3, are associated with a significant decrease in warfarin dose requirement, especially among Europeans. 19 A large number of studies concerning the influence of CYP2C9 genotype on warfarin dose have been published. [1] [2] [3] 5, 11, [20] [21] [22] [23] [24] There is as yet limited information regarding pharmacodynamic factors involved in variable response to warfarin. Warfarin acts through interference with the vitamin K cycle in the liver (Figure 1) . 25 It limits the regeneration of reduced vitamin K and, thus, limits the production of active clotting proteins. 26 The enzyme vitamin K epoxide reductase (VKOR) was identified as warfarin's target 30 years ago, 27, 28 but the actual enzyme proved difficult to purify. 29 The gene of the major protein component of VKOR was eventually mapped to human chromosome 16p12-q21, 30 and it was recently identified as VKOR complex subunit 1 (VKORC1). 31, 32 VKORC1 spans 4 kilobases (kb), consists of three exons (NM_024006), and encodes a 163 amino-acid enzyme located in the endoplasmic reticulum (NP_076869). Rare mutations that lead to familial defective vitamin K-dependent clotting factors and hereditary warfarin resistance have been found in human VKORC1.
31,33
Reduced vitamin K is a required cofactor for the activation of clotting factors II, VII, IX and X and proteins C, S and Z by gamma-glutamyl carboxylation (Figure 1) . 34 Human gamma-glutamyl carboxylase (GGCX) was identified almost 30 years ago. 35 In the mid-90s, the human enzyme was purified, 36 and the gene (GGCX) was mapped to human chromosome 2p12. 37, 38 GGCX spans 13 kb, contains 15 exons (NM_000821) and codes for a 758 amino-acid membrane protein of the endoplasmic reticulum and the Golgi apparatus (NP_000812). 35, 39 Two rare mutations in GGCX that cause deficiency of all vitamin K-dependent coagulation factors have been identified. 34 We attempt to evaluate whether common genetic variation in the vitamin K cycle affects warfarin dose requirement in an unselected population at a hospital anticoagulation clinic. Here we report a novel combination of factors that allows, for the first time, explanation of almost 60% of variable response to warfarin.
RESULTS
We selected all publicly available (dbSNP 121) singlenucleotide polymorphisms (SNPs) in the VKORC1 (chr16: 31013777-31009681 bp; NCBI build 35) and GGCX (chr2: 85700237-85687865 bp) genes, including 5 kb up-and downstream flanking regions. We designed MassExtend assays for 29 VKORC1 SNPs, including the mutations reported by Rost et al, 40 and for 16 GGCX SNPs and used them to type 201 warfarin-treated patients. Only SNPs without significant deviation from Hardy-Weinberg equilibrium were used in the statistical evaluation of the study.
We obtained results for 20 VKORC1 SNPs, with five of them being common in this sample. Four SNPs have minor allele frequencies (MAF) around 40% and are located 5 0 upstream (rs9923231), in the first intron (rs9934438), second intron (rs2359612) and 3 0 untranslated region (UTR) (rs7294) of the gene (Figure 2 ). The fifth SNP (rs11150606) is located downstream of the gene and has a MAF of 4%. Inter SNP distances are 2.8, 1.1, 1.5 and 3.3 kb, respectively. We applied the confidence intervals method with the HaploView software. 40 We found that the four most common SNPs are in strong linkage disequilibrium (LD), and give rise to three common haplotypes that are further subdivided into four by SNP rs11150606 (Figure 2 ). Note that, based on HapMap data (http://www.hapmap.org), this region of high LD extends up to 285 kb in Caucasians.
For GGCX, we obtained results for 14 SNPs, and, as shown in Figure 3 , nine SNPs have MAF above 30%. They are located in intron one (rs7568458), intron two (rs12714145), intron five (rs6738645), intron six (rs762684), exon eight (rs699664), exon nine (rs2592551), intron 14 (rs2028898) and in the 3 0 flanking region (rs6547621 and rs7605975). The exon eight SNP rs699664 leads to an arginine to glutamine change in codon 325, while rs2592551 in exon nine is synonymous. Inter-SNP distances are 0.8, 4.2, 1.1, 1.5, 0.4, 2.9, 2.6 and 2.1 kb, respectively. All nine SNPs are within a region of strong LD and define five common haplotypes ( Figure 3) .
Alleles of the five VKORC1 SNPs covary significantly with warfarin dose according to a regression model. Four of them are extremely closely associated with dose, Po0.0001 (Figure 4 ), while the fifth (rs11150606), which is located downstream of the gene and has a lower MAF, shows a less significant association, P ¼ 0.0221. All five SNPs are good predictors of warfarin maintenance dose, and explain 29-30% of inter-individual variability (Table 1 ). In the Figure 1 The vitamin K cycle. 25 VKOR reduces vitamin K. Reduced vitamin K is a cofactor for activation of clotting factors II, VII, IX and X and proteins C, S and Z by GGCX. In the process vitamin K is oxidised, and in the next cycle VKOR regenerates reduced vitamin K. Warfarin inhibits VKOR, impairing the synthesis of clotting factors. univariate model used, rs2359612 was a better predictor of warfarin maintenance dose than rs7294; addition of rs7294 to the model increased the explanatory value by only 3%. Note that rs9923231, rs9934438 and rs2359612 have pairwise r 2 values close to 1, implying that their genotypes are in near perfect concordance. In contrast to VKORC1, only one of the studied GGCX SNPs reaches statistical significance, rs12714145 (intron 2), P ¼ 0.0360 ( Figure 5 ). GGCX SNPs rs762684 (intron 6) and rs2592551 (exon 9) also show a tendency towards association with warfarin dose (P ¼ 0.0613 and 0.0870). The mean warfarin dose associated with each VKORC1 and GGCX haplotype was calculated (Figures 2 and 3) . A global test for statistical difference among the haplotype means revealed a highly significant difference among VKORC1 haplotypes (global Pp4.73 Â 10 À9 ), but not among GGCX haplotypes (global P ¼ 0.757). To characterise warfarin dose differences among VKORC1 haplotypes, the means for each pair of haplotypes were statistically compared ( Table 2 ). Haplotypes that share alleles at the first three SNPs (rs9923231, rs9934438 and rs2359612) do not exhibit significant differences in warfarin dose; G-C-C haplotypes H1 vs H2 (P ¼ 0.09), and A-T-T haplotypes H3 vs H4 (P ¼ 0.54). However, every pair of haplotypes with different alleles at the first three SNPs (G-C-C vs A-T-T) shows significant differences (P ¼ 1.26 Â 10 À9 to 0.0163). Concomitant medication is divided into three groups: drugs with no interaction, drugs that potentiate and drugs that decrease the effect of warfarin. Indication for treatment is divided into two groups: heart valve prosthesis and other indications. The factors VKORC1 SNP rs2359612, CYP2C9 variants *2 and *3, age, bodyweight (BW), concomitant medication, gender, the indication for treatment and PT INR value are tested for covariance with warfarin maintenance dose and dose/ bodyweight using univariate analysis in SAS. The explanatory value of VKORC1 SNP rs9923231 was still higher, r 2 ¼ 0.30 for dose and r 2 ¼ 0.27 for dose/BW, based on 174 genotyped patients.
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To increase the power to predict variable warfarin sensitivity, we combined VKORC1 genotyping results with other genetic and nongenetic factors. Polymorphisms in the liver enzyme CYP2C9, which metabolises warfarin, are known to be associated with warfarin sensitivity. [1] [2] [3] 5, 11, [20] [21] [22] [23] [24] Our subjects have previously been genotyped for CYP2C9, and the frequency of CYP2C9 homozygous extensive metabolisers was 66.7%, heterozygous extensive metabolisers 31.3% and poor metabolisers 2.0%. 3 The combined effect of VKORC1 and CYP2C9 on warfarin dose is presented in Figure 6 , which shows that VKORC1 has a clear effect on all extensive metabolisers. In a multiple model, VKORC1, CYP2C9, age, bodyweight, interacting drugs, and indication for treatment together account for 56.0% of the total inter-individual variance in warfarin response ( Table 3 ). The explanatory value increases marginally to 57.4%, when GGCX is added to the model.
DISCUSSION
Warfarin acts by interfering with VKOR, which catalyses an essential step in the activation of several blood-clotting Figure 6 Box and whisker plot of mean weekly warfarin doses for different genotypes of VKORC1 (SNP rs2359612) and CYP2C9 (alleles *1, *2, *3). The horizontal line indicates the median, the box covers the 25-75% percentiles and the maximum length of each whisker is 1.5 times the interquartile range. Points outside this show up as outliers. Maintenance dose of warfarin was significantly related to VKORC1 and CYP2C9 genotypes. 
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proteins. The discovery of rare mutations in VKORC1 and GGCX causing deficiency in vitamin K-dependent clotting factors, and for VKORC1 also hereditary warfarin resistance were presented last year. 31, 34 This led us to test the hypothesis that common polymorphisms in these genes affect warfarin response in the general population.
It is well known that polymorphisms in CYP2C9 are associated with warfarin sensitivity. 3 An Italian group lead by Margaglione recently described an association between warfarin dose and genotypes of CYP2C9 and two noncoding VKORC1 SNPs (rs9934438 and rs7294) in 147 patients. 41 In their study, CYP2C9 and VKORC1 together account for 35% of interindividual variability. In our material, CYP2C9 and VKORC1 together explain 40% of variance in dose, and VKORC1 is the better predictor of the two. In contrast, in the Italian study, CYP2C9 has a larger impact on dose than VKORC1. This discrepancy could be due to the fact that CYP2C9 variant alleles are more frequent in the Italian population than in the Swedish.
1,41,42 In Margaglione's study, the allele frequencies of CYP2C9*2 and *3 were 17.0% and 8.8%, respectively, 41 as compared with our figures of 11.2% and 6.5%. 3 On the other hand, there was no major difference between populations in the frequency of the intragenic VKORC1 SNP rs9934438: MAF 39.8% in the Italians, and 38.8% in the Swedes. 41 All the studied VKORC1 polymorphisms are non-coding, and do not change the molecular structure of the enzyme. The observed association between polymorphisms and dose variation could instead be due to one of the alleles affecting mRNA transcription, splicing or stability. This effect may be mediated by one of the analysed SNPs or by an unidentified causal variant in LD with the alleles studied here.
A Japanese group reported an association between genetic variants in GGCX and warfarin dose. 43 They showed that warfarin dose increased with the number of microsatellite (CAA)n repeats in intron 6. Interestingly, the GGCX SNP in intron 6 shows the same trend, but in our material a SNP in intron 2 was the best predictor of warfarin dose. In fact, all the tested GGCX SNPs are in high LD, and it is therefore not surprising that several SNPs show the same trend.
Knowledge of biochemical mechanisms, site of drug action and the human genome enables discovery of new genetic factors that cause variable drug response. By combining genotyping with accurate clinical measurements, it should be possible to develop an effective algorithm for individualised drug treatment using genetic and clinical factors. Already, more than half the variance in maintenance warfarin dose is explained by VKORC1, CYP2C9 and four patient characteristics. This compares favourably with the recently published value of 39% that was obtained using a predictive dosage algorithm based on CYP2C9 and seven clinical and demographic factors. 44 Verification of our findings and continued search for additional factors will be performed in a larger patient cohort. These results will eventually enable prediction of individualised dosage in the initiation phase of warfarin therapy, and minimise the risk of early haemorrhage without compromising anticoagulant effect. This strategy may also be used to identify warfarin-sensitive patients, who require one of the expensive novel anticoagulants. Implementation of personalised warfarin treatment would therefore be both beneficial and cost-effective.
MATERIALS AND METHODS
Patients
This study was approved by the local Ethics Committee. After informed consent, we enrolled 201 patients that were treated with warfarin at the anticoagulation clinic at Uppsala University Hospital. 3 The patients were essentially Caucasian; 194 being of Swedish origin, four of other European descent and three from the Middle East. When the patients were recruited in 2000, they were 28-88 years old (Table 1) . They had been treated with warfarin for at least 2 months (range 2.4 months-26 years, median 2 years). At six consecutive visits, five weekly warfarin doses and five corresponding PT INR values were registered. Individual warfarin dose requirement ranged from 4.5 to 77.25 mg/ week. Information about age, gender, bodyweight (missing in seven patients), other diseases and indication for treatment was taken from the patients' medical records (Table 4) . Patients were stratified into two treatment groups: patients with heart valve prosthesis, where a higher target INR usually is recommended and patients treated for other indications. Concurrent medications were registered, and drugs were classified as interacting if they had moderate or major interactions with warfarin according to the database MICROMEDEX s Healthcare Series (http://www. micromedex.com/ in May 2002). The patients had a total of 107 concurrent medications known to influence warfarin (Table 4) . Patients were divided into three groups: individuals with drugs that lower the effect of warfarin by inducing its metabolism (n ¼ 4), those with medications that potentiate the effect of warfarin (n ¼ 74) and patients without any known interactions (n ¼ 123). Whole blood was collected from all patients, and DNA was extracted using standard procedures. 
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Genotyping SNP sequences were downloaded from the dbSNP database (build 121) and assays were designed with the SpectroDESIGNERt software. SNP typing was performed using the MassARRAYt platform (Sequenom, Hamburg, Germany). Primer sequences are listed in Table 5 . Polymerase chain reaction (PCR) amplification was performed in 5-ml reactions using 3.5 ng DNA and 150 nM of each forward and reverse primer, 200 mM deoxynucleotide triphosphates (dNTPs), 1 Â PCR buffer and 0.04 U Titanium s polymerase (BD BioSciences, Clontech, CA, USA). Cycling conditions were 941C for 15 min, followed by 45 cycles of 941C for 20 s, 561C for 30 s and 721C for 1 min, and then 721C for 3 min. Primer extension, sample clean-up and MALDI-TOF mass spectrometry analysis were performed as described by Whittaker et al. 45 Genotyping was carried out at a multiplex level of four SNPs per well and data quality was assessed by duplicate DNAs (n ¼ 4). SNPs with more than one discrepant call were Table 5 PCR primers and extend primers for the genotyping reactions A patient can have more than one indication, concurrent disease and interacting medication, and only the most common ones are shown. Drugs potentiating the effect of warfarin are indicated by s and drugs decreasing its effect by r.
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removed. Finally, we removed loci with results for less than 80% of individuals or zero heterozygosity, and we flagged markers out that were not in Hardy-Weinberg equilibrium (w 2 X10).
Statistical Analysis
We assessed the quality of the genotype data by testing for Hardy-Weinberg equilibrium. Univariate and multiple analyses of predictor's impact on warfarin dose were calculated using linear regression models (as implemented by SAS software 
